{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T06:21:31Z","timestamp":1790662891921,"version":"4.1.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2019,12,19]],"date-time":"2019-12-19T00:00:00Z","timestamp":1576713600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,12,19]],"date-time":"2019-12-19T00:00:00Z","timestamp":1576713600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Janssen-Cilag Pty Ltd","award":["-"],"award-info":[{"award-number":["-"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2020,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background and objectives<\/jats:title>\n<jats:p>The purpose of this study was to develop an understanding of treatment preferences in patients with inflammatory arthritis (IA) [rheumatoid arthritis (RA), ankylosing spondylitis (AS) and psoriatic arthritis (PsA)] focussing on treatment attributes that patients\u2019 value, their relative importance, and the risk-benefit trade-offs that characterise patients\u2019 choices around treatment.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>A discrete choice experiment (DCE) approach was used. Attributes of interest were clinical efficacy; slowing of disease progression; risk of mild-moderate side effects; risk of severe side effects; frequency of administration; real-world product evidence; management of related conditions; and availability of a patient support programme. Using data from the DCE component, a restricted latent class model (LCM) was estimated to determine discrete \u2018classes\u2019 of treatment preferences.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>In this analysis, 206 participants were included (AS n = 59; PsA n = 62; RA n = 85). Two classes were identified. For \u2018class 1\u2019 (59.9%), the most important attributes (across all treatment modalities) were preventing disease progression, clinical efficacy and risk of mild-to-moderate side effects. For \u2018class 2\u2019 (40.1%), clinical and non-clinical attributes were important, and attribute importance depended on treatment modality. Patient demographic and treatment characteristics did not predict class membership.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusion<\/jats:title>\n<jats:p>For most patients with IA, clinical efficacy, stopping disease progression and risks of mild-to-moderate side effects are important treatment attributes. Patients with prior biologic DMARD experience had greater preference for injection treatments. For a subset of patients, patient support programmes and the frequency of administration were important. Clinicians should be mindful of preferences when prescribing treatment to patients with IA.<jats:table-wrap><jats:table><jats:tbody><jats:tr><jats:td colspan=\"2\"><jats:bold>Key Points<\/jats:bold><jats:italic>\u2022 Most patients consider clinical efficacy, stopping disease progression and the risk of mild-to-moderate side effects as important treatment attributes<\/jats:italic><jats:italic>\u2022 Patients with prior biologic DMARD experience have greater preference for injection treatments.<\/jats:italic><jats:italic>\u2022 For a subset of patients, patient support programmes, and the frequency of administration were important.<\/jats:italic><jats:italic>\u2022 Clinicians should be mindful of preferences when prescribing treatment to patients with IA.<\/jats:italic><\/jats:td><\/jats:tr><\/jats:tbody><\/jats:table><\/jats:table-wrap><\/jats:p>\n<\/jats:sec>","DOI":"10.1007\/s10067-019-04843-4","type":"journal-article","created":{"date-parts":[[2019,12,19]],"date-time":"2019-12-19T23:02:37Z","timestamp":1576796557000},"page":"1077-1089","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["What do Australian patients with inflammatory arthritis value in treatment? A discrete choice experiment"],"prefix":"10.1007","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2635-2568","authenticated-orcid":false,"given":"Kerrie-Anne","family":"Ho","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9173-9956","authenticated-orcid":false,"given":"Mustafa","family":"Acar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7730-6310","authenticated-orcid":false,"given":"Andrea","family":"Puig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabor","family":"Hutas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5221-0067","authenticated-orcid":false,"given":"Simon","family":"Fifer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,12,19]]},"reference":[{"key":"4843_CR1","unstructured":"The Royal Australian College of General Practitioners (2009) Recommendations for the diagnosis and management of early rheumatoid arthritis. South Melbourne, VIC"},{"issue":"2","key":"4843_CR2","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1007\/s40744-017-0083-1","volume":"4","author":"RH Borse","year":"2017","unstructured":"Borse RH, Brown C, Muszbek N, Chaudhary MA, Kachroo S (2017) Cost-Effectiveness of golimumab in ankylosing spondylitis from the UK Payer Perspective. Rheumatol Ther 4(2):427\u2013443. https:\/\/doi.org\/10.1007\/s40744-017-0083-1","journal-title":"Rheumatol Ther"},{"issue":"4","key":"4843_CR3","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1080\/03009740902748264","volume":"38","author":"JL Hoving","year":"2009","unstructured":"Hoving JL, Bartelds GM, Sluiter JK, Sadiraj K, Groot I, Lems WF, Dijkmans BAC, Wijbrandts CA, Tak PP, Nurmohamed MT, Voskuyl AE, Frings-Dresen MHW (2009) Perceived work ability, quality of life, and fatigue in patients with rheumatoid arthritis after a 6-month course of TNF inhibitors: prospective intervention study and partial economic evaluation. Scand J Rheumatol 38(4):246\u2013250. https:\/\/doi.org\/10.1080\/03009740902748264","journal-title":"Scand J Rheumatol"},{"issue":"1085","key":"4843_CR4","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1136\/postgradmedj-2015-133419","volume":"92","author":"D Wcis\u0142o-Dziadecka","year":"2016","unstructured":"Wcis\u0142o-Dziadecka D, Zbiciak-Nylec M, Brzezi\u0144ska-Wcis\u0142o L, Mazurek U (2016) TNF-\u03b1 in a molecularly targeted therapy of psoriasis and psoriatic arthritis. Postgrad Med J 92(1085):172\u2013178. https:\/\/doi.org\/10.1136\/postgradmedj-2015-133419","journal-title":"Postgrad Med J"},{"key":"4843_CR5","doi-asserted-by":"publisher","first-page":"335","DOI":"10.2147\/PPA.S5835","volume":"3","author":"JL Barton","year":"2009","unstructured":"Barton JL (2009) Patient preferences and satisfaction in the treatment of rheumatoid arthritis with biologic therapy. Patient Prefer Adherence 3:335\u2013344","journal-title":"Patient Prefer Adherence"},{"issue":"4","key":"4843_CR6","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1037\/h0070288","volume":"34","author":"LL Thurstone","year":"1927","unstructured":"Thurstone LL (1927) A law of comparative judgment. Psychol Rev 34(4):273\u2013286. https:\/\/doi.org\/10.1037\/h0070288","journal-title":"Psychol Rev"},{"issue":"2","key":"4843_CR7","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1086\/259131","volume":"74","author":"KJ Lancaster","year":"1966","unstructured":"Lancaster KJ (1966) A new approach to consumer theory. J Polit Econ 74(2):132\u2013157","journal-title":"J Polit Econ"},{"key":"4843_CR8","first-page":"105","volume-title":"Frontiers of econometrics","author":"D McFadden","year":"1974","unstructured":"McFadden D (1974) Conditional logit analysis of qualitative choice behaviour. In: Zarembka P (ed) Frontiers of econometrics. Academic Press, New York, pp 105\u2013142"},{"key":"4843_CR9","doi-asserted-by":"publisher","first-page":"2217","DOI":"10.2147\/PPA.S117774","volume":"10","author":"R Alten","year":"2016","unstructured":"Alten R, Kruger K, Rellecke J, Schiffner-Rohe J, Behmer O, Schiffhorst G, Nolting HD (2016) Examining patient preferences in the treatment of rheumatoid arthritis using a discrete-choice approach. Patient Prefer Adherence 10:2217\u20132228. https:\/\/doi.org\/10.2147\/PPA.S117774","journal-title":"Patient Prefer Adherence"},{"issue":"2","key":"4843_CR10","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.jval.2012.11.007","volume":"16","author":"F Augustovski","year":"2013","unstructured":"Augustovski F, Beratarrechea A, Irazola V, Rubinstein F, Tesolin P, Gonzalez J, Lencina V, Scolnik M, Waimann C, Navarta D, Citera G, Soriano ER (2013) Patient preferences for biologic agents in rheumatoid arthritis: a discrete-choice experiment. Value Health 16(2):385\u2013393. https:\/\/doi.org\/10.1016\/j.jval.2012.11.007","journal-title":"Value Health"},{"issue":"11","key":"4843_CR11","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1093\/rheumatology\/kew280","volume":"55","author":"GS Hazlewood","year":"2016","unstructured":"Hazlewood GS, Bombardier C, Tomlinson G, Thorne C, Bykerk VP, Thompson A, Tin D, Marshall DA (2016) Treatment preferences of patients with early rheumatoid arthritis: a discrete-choice experiment. Rheumatology (Oxford) 55(11):1959\u20131968. https:\/\/doi.org\/10.1093\/rheumatology\/kew280","journal-title":"Rheumatology (Oxford)"},{"issue":"11","key":"4843_CR12","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1136\/ard.2003.019422","volume":"63","author":"L Fraenkel","year":"2004","unstructured":"Fraenkel L (2004) Patient preferences for treatment of rheumatoid arthritis. Ann Rheum Dis 63(11):1372\u20131378. https:\/\/doi.org\/10.1136\/ard.2003.019422","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"4843_CR13","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1186\/s12913-018-3484-0","volume":"18","author":"S Fifer","year":"2018","unstructured":"Fifer S, Rose J, Hamrosi KK, Swain D (2018) Valuing injection frequency and other attributes of type 2 diabetes treatments in Australia: a discrete choice experiment. BMC Health Serv Res 18(1):675. https:\/\/doi.org\/10.1186\/s12913-018-3484-0","journal-title":"BMC Health Serv Res"},{"issue":"2","key":"4843_CR14","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s40273-017-0575-4","volume":"36","author":"M Zhou","year":"2018","unstructured":"Zhou M, Thayer WM, Bridges JFP (2018) Using latent class analysis to model preference heterogeneity in health: a systematic review. Pharmacoeconomics 36(2):175\u2013187. https:\/\/doi.org\/10.1007\/s40273-017-0575-4","journal-title":"Pharmacoeconomics"},{"key":"4843_CR15","doi-asserted-by":"publisher","first-page":"2153","DOI":"10.2147\/PPA.S168458","volume":"12","author":"L Scalone","year":"2018","unstructured":"Scalone L, Sarzi-Puttini P, Sinigaglia L, Montecucco C, Giacomelli R, Lapadula G, Olivieri I, Giardino AM, Cortesi PA, Mantovani LG, Mecchia M (2018) Patients', physicians', nurses', and pharmacists' preferences on the characteristics of biologic agents used in the treatment of rheumatic diseases. Patient Prefer Adherence 12:2153\u20132168. https:\/\/doi.org\/10.2147\/PPA.S168458","journal-title":"Patient Prefer Adherence"},{"key":"4843_CR16","doi-asserted-by":"crossref","unstructured":"Hensher DA, Rose JM, Greene WH (2015) Applied choice analysis. A Primer. 2nd. edn. Cambridge University Press, Cambridge","DOI":"10.1017\/CBO9781316136232"},{"issue":"10","key":"4843_CR17","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1093\/rheumatology\/kev113","volume":"54","author":"M Harrison","year":"2015","unstructured":"Harrison M, Marra C, Shojania K, Bansback N (2015) Societal preferences for rheumatoid arthritis treatments: evidence from a discrete choice experiment. Rheumatology (Oxford) 54(10):1816\u20131825. https:\/\/doi.org\/10.1093\/rheumatology\/kev113","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"4843_CR18","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1002\/hec.1739","volume":"21","author":"J Coast","year":"2012","unstructured":"Coast J, Al-Janabi H, Sutton EJ, Horrocks SA, Vosper AJ, Swancutt DR, Flynn TN (2012) Using qualitative methods for attribute development for discrete choice experiments: issues and recommendations. Health Econ 21(6):730\u2013741. https:\/\/doi.org\/10.1002\/hec.1739","journal-title":"Health Econ"},{"issue":"5","key":"4843_CR19","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1080\/01441640902827623","volume":"29","author":"JM Rose","year":"2009","unstructured":"Rose JM, Bliemer MCJ (2009) Constructing efficient stated choice experimental designs. Transp Rev 29(5):587\u2013617. https:\/\/doi.org\/10.1080\/01441640902827623","journal-title":"Transp Rev"},{"issue":"4","key":"4843_CR20","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1002\/art.10515","volume":"47","author":"T Heiberg","year":"2002","unstructured":"Heiberg T, Kvien TK (2002) Preferences for improved health examined in 1,024 patients with rheumatoid arthritis: pain has highest priority. Arthritis Rheum 47(4):391\u2013397. https:\/\/doi.org\/10.1002\/art.10515","journal-title":"Arthritis Rheum"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-019-04843-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10067-019-04843-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-019-04843-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,18]],"date-time":"2020-12-18T00:45:54Z","timestamp":1608252354000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10067-019-04843-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,19]]},"references-count":20,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["4843"],"URL":"https:\/\/doi.org\/10.1007\/s10067-019-04843-4","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,19]]},"assertion":[{"value":"2 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"MA, AP and GH are employees of Janssen-Cilag, who manufacture golimumab (SIMPONI\u00ae) and ustekinumab (STELARA\u00ae). KH and SF are employees of CaPPRe who were contracted by Janssen-Cilag to perform the experiments, provide data management and conduct the analysis.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}